Table 2 Effects of AEE on potential biomarkers associated with atherosclerosis in plasma.

1

9.97

5.94

C₂₄H₅₀NO₇P

LysoPC (16:0)

[M+H]⁺

496.3401

1.14^*

1.24^**

Glycerophospholipid metabolism

2

10.36

5.74

C₂₆H₅₂NO₇P

LysoPC (18:1)

[M+H]+

522.3560

2.07^**

1.25^**

Glycerophospholipid metabolism

3

12.15

4.01

C₂₆H₅₄NO₇P

LysoPC (18:0)

[M+H]+

524.3718

1.22^*

1.18^*

Glycerophospholipid metabolism

4

10.06

2.01

C₃₀H₅₂NO₇P

LysoPC (22:5)

[M+H]+

570.3559

5.59^**

1.12

Glycerophospholipid metabolism

5

9.46

3.27

C₂₈H₅₀NO₇P

LysoPC (20:4)

[M+H]+

544.3403

1.79^**

1.15

Glycerophospholipid metabolism

6

1.48

1.86

C₆H₁₃NO₂

Leucine

[M+H]+

132.1020

0.50^**

1.68^**

Amino acid metabolism

7

12.24

1.70

C₂₈H₅₂NO₇P

LysoPC (20:3)

[M+H]+

546.3534

1.06

1.97

Glycerophospholipid metabolism

8

1.19

1.58

C₅H₁₁NO₂

Valine

[M+H]+

118.0861

0.51^**

2.22^*

Amino acid metabolism

9

10.97

1.52

C₂₃H₄₈NO₇P

LysoPC (15:0)

[M+H]+

482.3357

1.00

8.44^**

Glycerophospholipid metabolism

10

8.52

1.44

C₂₂H₄₆NO₇P

LysoPC (14:0)

[M+H]+

468.3090

8.54^**

1.08

Glycerophospholipid metabolism

11

8.98

1.34

C₂₄H₄₈NO₇P

LysoPC (16:1)

[M+H]+

494.3244

1.70^*

1.26

Glycerophospholipid metabolism

12

12.28

1.54

C₂₂H₃₂O₂

DHA

[M−H]−

327.2349

0.57^**

0.75

Biosynthesis of unsaturated fatty acids

13

14.73

2.33

C₁₈H₃₄O₂

Elaidic acid

[M−H]−

281.2506

1.75^**

1.1

Biosynthesis of unsaturated fatty acids